Can a Ganglioside Stop Huntington's Disease
Intracerebroventricular infusion of GM1 resulted in numerous improvements in neuropathology, behavior, and cognition in HD mice models
Gene Therapy for HD Gets FDA Orphan Designation
AMT-130 has a AAV5 vector carrying an artificial micro-RNA designed to silence the mutant huntingtin gene.
Are HD Clinical Trials Measuring the Right Outcome Measure?
A new study recently published in
may have found a solution to the factors limiting HD clinical trials.
NIH Awards $2.5 Million Grant to HD Wearables
HDWear, a technology that utilizes sensors to monitor motor function of Huntington’s disease patients, has received more than $2.5 million from the NIH.
Global HD Organizations Launch Collaborative Advocacy Group
Three global Huntington’s disease patient advocacy organizations have teamed up to give those affected by the disease a voice in clinical research.
George Yohrling, Ph.D Discusses Current and Potential HD Treatment Options
George Yohrling, PhD discusses treatment for Huntington's disease patients, therapies in the pipeline and why it’s an exciting time for the research community.
Being Patient-Facing in the Huntington's Disease Space
New Gene Linked to Huntington's Disease Progression
Results from a recent study published in Lancet Neurology by researchers in England and Wales identifies a gene linked to Huntington’s disease progression.
Gene Therapy for Huntington's Disease in Development
In Huntington's disease animal models, AMT-130, an AAV5 vector carrying a DNA cassette encoding artificial micro-RNA, is effective.
Discussing the Importance of the HDSA
Louise Vetter, CEO of the HDSA and George Yohrling, PhD discuss the creation of the organization, what motivates them, and why their work is so important.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.